Advertisement

Topics

Diagnostics and Therapeutics for Adrenocortical Carcinomas

14:37 EDT 12 Jul 2018 | NIH

The National Cancer Institute's Endocrine Oncology Branch seeks parties to co-develop diagnostic that target altered human miRNA expression such as miRNA-483 and miRNA 100 to accurately predict if a patient's adrenal cortex tumor is benign or malignant.

Adrenocortical carcinomas (ACC) are rare but aggressive cancers and typically have a poor prognosis.  Currently, there are limited options for molecular diagnosis to distinguish malignant tumors from benign tumors of this type.  As a result there are few treatment strategies for ACC.

This technology describes that altered human miRNA expression such as miRNA-483 and miRNA 100 can accurately predict if a patient''''s adrenal cortex tumor is benign or malignant. Additionally, preliminary results suggest that altering the expression of this miRNA in ACC cells can effect cancer cell growth.  Therefore, inhibiting a miRNA may serve as a therapeutic option for ACC.

NIH Ref. No.: 
E-026-2011
Advantages: 
  • Distinguishes malignant Adrenal cortex tumor from a benign tumor, options for such distinction are limited at this time.
Applications: 
  • Technology can be developed into a diagnostic and prognostic marker for ACC.
  • Inhibiting miRNA can serve as a potential therapeutics for ACC.
Development Status: 

Pre-clinical (in vivo)

Updated On: 
May 30, 2018
Provider Classifications: 
Patent Application: 
12/961,298
Publications: 
Patent Authority: 
U.S. Provisional
Licensing Contacts: 
Lead Inventor: 
LPM FIrst Name: 
John
LPM Last Name: 
Hewes
Inv Is lead: 
LPM Phone: 
240-276-5515
LPM Suffix: 
Ph.D.
LPM Organization: 
NCI - National Cancer Institute
DTDT Classification: 
Therapeutics
DTDT Description: 
Therapeutics
Pat Filing Date: 
2010-12-06
Publication Link: 
https://www.ncbi.nlm.nih.gov/pubmed/21472710
https://www.ncbi.nlm.nih.gov/pubmed/?term=22241719
Publication Caption: 
PMID: 21472710
PMID: 22241719
Publication Title: 

Patterson E, et al. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy.

Patterson E, et al. The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma.

Collaboration Sought: 
Yes
Collaboration Opportunity: 

Licensing only

E Number Only: 
E-026-2011
Inventor First Name: 
Electron
Inventor Last Name: 
Kebebew

Original Article: Diagnostics and Therapeutics for Adrenocortical Carcinomas

NEXT ARTICLE

More From BioPortfolio on "Diagnostics and Therapeutics for Adrenocortical Carcinomas"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

MicroRNAs (miRNAs)
A microRNA (abbreviated miRNA) is a small non-coding RNA molecule (containing about 22 nucleotides) found in plants, animals, and some viruses.  Key findings: miRNA is involved in the normal functioning of eukaryotic cells, so has dysregulation...